Midatech Pharma signs supply agreement with Turkey's Centurion Pharma
Tuesday, December 15, 2015
Midatech Pharma, the specialty pharmaceutical company focused on the development and commercialisation of multiple therapeutic products, today announces that the Company has entered into a supply agreement for Q-Octreotide with Centurion Pharma (“Centurion”), a Turkish company focused on the development and commercialisation of specialty products for the Turkish market.
The agreement grants exclusive rights to Q-Octreotide, a sustained release version of Octreotide which Midatech is developing for the treatment of carcinoid and acromegaly, to Centurion for the Turkish market. Midatech’s Q-Octreotide is aimed at offering patients and physicians an alternative therapy for carcinoid and acromegaly with distinct advantages including ease of reconstitution and administration.
As part of the agreement, Midatech will receive up front, milestone and royalty payments. Financial terms of the agreement have not been disclosed.
midatechpharma.com
